Zobrazeno 1 - 10
of 668
pro vyhledávání: '"James, A Kaye"'
Publikováno v:
Thyroid Research, Vol 15, Iss 1, Pp 1-14 (2022)
Abstract Background Medullary thyroid cancer (MTC) accounts for approximately 1.6% of new cases of thyroid cancer. The objective of this study was to describe patient characteristics, biomarker testing, treatment patterns, and clinical outcomes among
Externí odkaz:
https://doaj.org/article/4120145804354a169a8aeb7bf6b0c7f1
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2690-2702 (2021)
Abstract Background Information on overall survival (OS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We therefore conducted a population‐based retrospective cohort study to
Externí odkaz:
https://doaj.org/article/ee10a73acaf446daa5e76ae59e569ae3
Publikováno v:
Cancer Medicine, Vol 8, Iss 8, Pp 3803-3810 (2019)
Abstract Introduction Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and assessed tre
Externí odkaz:
https://doaj.org/article/8f0d4103cfdf4d6096dda24a3ec502d5
Autor:
Adrian D. Vickers, Katherine B. Winfree, Gebra Cuyun Carter, Urpo Kiiskinen, Min-Hua Jen, Donald Stull, James A. Kaye, David P. Carbone
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-16 (2019)
Abstract Background Locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after first-line treatment has a poor prognosis. Recent randomized clinical trials (RCTs) have demonstrated survival benefits of alternative tre
Externí odkaz:
https://doaj.org/article/372369967d9c4a9cb9d9327001d909f8
Publikováno v:
Perspectives in Public Health; April 1929, Vol. 50 Issue: 4 p264-269, 6p
Autor:
Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, Mohamad Mohty
Publikováno v:
Advances in Hematology, Vol 2019 (2019)
Background. Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. Methods. A retrospective medical record
Externí odkaz:
https://doaj.org/article/d1602ce2e4904f4dab213fe183f4e6f9
Autor:
Catherine W. Saltus, Zdravko P. Vassilev, Jihong Zong, Brian Calingaert, Elizabeth B. Andrews, Montse Soriano-Gabarró, James A. Kaye
Publikováno v:
Prostate Cancer, Vol 2019 (2019)
Background. New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with CRPC in the Surveil
Externí odkaz:
https://doaj.org/article/8d3daf93f18f46fa8d766d535be4ca7f
Autor:
Alison Tse Kawai, David Martinez, Catherine W. Saltus, Zdravko P. Vassilev, Montse Soriano-Gabarró, James A. Kaye
Publikováno v:
Prostate Cancer, Vol 2019 (2019)
Background and Objective. Skeletal-related events (SREs) are common in men with bone metastases and have negative consequences for patients with castration-resistant prostate cancer (CRPC), including pain, reduced quality of life, and increased morta
Externí odkaz:
https://doaj.org/article/961af6cb49cb4c9486187b5ccaaf0743
Autor:
Catherine W. Saltus, Zdravko P. Vassilev, Jihong Zong, Brian Calingaert, Elizabeth B. Andrews, Montse Soriano-Gabarró, James A. Kaye
Publikováno v:
Prostate Cancer, Vol 2019 (2019)
Externí odkaz:
https://doaj.org/article/805b8c9dddce412ca1f527cd7c242530
Autor:
Blánaid Hicks, James A. Kaye, Laurent Azoulay, Kasper Bruun Kristensen, Laurel A. Habel, Anton Pottegård
Publikováno v:
Hicks, B, Kaye, J A, Azoulay, L, Bruun Kristensen, K, Habel, L A & Pottegård, A 2023, ' The application of lag times in cancer pharmacoepidemiology: a narrative review ', Annals of Epidemiology, vol. 84, pp. 25-32 . https://doi.org/10.1016/j.annepidem.2023.05.004
PurposeWith the increasing utilization of medications worldwide, coupled with the increasing availability of long-term data, there is a growing opportunity and need for robust studies evaluating drug–cancer associations. One methodology of importan